⚠️ Ibogaine causes QT interval prolongation in virtually all patients and has been associated with fatal cardiac arrhythmias. Comprehensive cardiac screening is not optional — it is a life-or-death prerequisite. Multiple documented deaths have occurred in individuals who received ibogaine without adequate cardiac evaluation.

Cardiac Screening Before Ibogaine Treatment: A Complete Guide

Ibogaine's most serious and well-documented risk is cardiotoxicity. The drug directly affects cardiac ion channels — particularly the hERG potassium channel — prolonging the QT interval and creating conditions that can trigger fatal ventricular arrhythmias, including torsades de pointes and ventricular fibrillation. A rigorous pre-treatment cardiac workup is the single most important safety step before any ibogaine administration. This guide explains exactly what that screening involves, why each element matters, and what findings disqualify someone from treatment.

Why Ibogaine Is Uniquely Cardiotoxic

Ibogaine and its primary metabolite noribogaine block the hERG (human ether-à-go-go-related gene) potassium channel, which governs cardiac repolarization. This blockade prolongs the QTc (corrected QT) interval on an electrocardiogram (ECG). When QTc exceeds approximately 500 ms — or when it increases by more than 60 ms from baseline — the risk of torsades de pointes, a potentially fatal polymorphic ventricular tachycardia, increases substantially (Koenig et al., 2020; Litjens & Brunt, 2016).

In clinical observational data, QTc prolongation following ibogaine administration has been recorded as high as 100 ms above baseline in some patients (Meisner et al., 2022). Noribogaine has a half-life of 24–72 hours, meaning cardiac effects persist well into the recovery period — not just during the acute psychedelic experience.

A 2012 review by Alper et al. catalogued 19 deaths associated with ibogaine, the majority attributed to cardiac causes, and found that many decedents had identifiable pre-existing risk factors that adequate screening would have flagged. Subsequent analyses have continued to associate fatalities with unscreened structural heart disease, drug interactions, and electrolyte abnormalities.

Required Cardiac Screening Components

1. 12-Lead Electrocardiogram (ECG)

A 12-lead ECG is the cornerstone of ibogaine cardiac screening and is required by every responsible clinical protocol. It must be performed within 30 days of treatment — many protocols require it within 7–14 days — because cardiac status can change rapidly, particularly in patients using opioids, stimulants, or alcohol.

What the ECG must measure and screen for:

  • QTc interval (Bazett or Fridericia correction): Most clinical protocols use a cutoff of QTc ≤ 450 ms in men and QTc ≤ 470 ms in women as the upper limit for treatment eligibility. Some conservative protocols set the threshold at 440 ms for all patients. A QTc above these thresholds is a hard contraindication.
  • PR interval: Prolonged PR (>200 ms) indicates first-degree AV block; higher-degree blocks are contraindications.
  • QRS duration: Widening (>120 ms) may indicate bundle branch block or sodium channel dysfunction.
  • ST-segment and T-wave abnormalities: May indicate ischemia, electrolyte disturbances, or structural disease.
  • Rhythm: Any significant arrhythmia — atrial fibrillation, frequent premature ventricular contractions (PVCs), ventricular tachycardia — must be evaluated and addressed before treatment.
  • Evidence of prior myocardial infarction: Pathological Q waves.
  • Wolff-Parkinson-White (WPW) pattern: Accessory pathway conduction is a contraindication.

The ECG must be read by a physician (ideally a cardiologist) — not self-interpreted. Borderline QTc values (440–460 ms) warrant cardiology consultation before proceeding.

2. Comprehensive Metabolic Panel and Electrolyte Assessment

Electrolyte abnormalities are independent risk factors for QT prolongation and arrhythmia, and they are extremely common in patients seeking ibogaine treatment — particularly those with histories of opioid use disorder, alcohol use disorder, or stimulant use, which are associated with malnutrition and dehydration.

Required labs:

  • Serum potassium (K⁺): Hypokalemia (<3.5 mEq/L) significantly amplifies QT prolongation. Target ≥3.8–4.0 mEq/L before treatment.
  • Serum magnesium (Mg²⁺): Hypomagnesemia (<1.7 mg/dL) is an underrecognized QT risk. Target ≥2.0 mg/dL. Magnesium supplementation is standard pre-treatment protocol in most clinics.
  • Serum calcium: Hypocalcemia prolongs QT independently.
  • Basic metabolic panel: Creatinine and BUN assess kidney function, relevant for drug clearance and electrolyte regulation.
  • Liver function tests (LFTs): Ibogaine is metabolized by CYP2D6 and CYP3A4. Hepatic impairment alters drug metabolism and can cause dangerous plasma level accumulation.
  • Complete blood count (CBC): Screens for anemia (increases cardiac demand) and infection.
  • Thyroid-stimulating hormone (TSH): Both hyperthyroidism and hypothyroidism affect cardiac rhythm and QT interval.

3. Detailed Medication and Substance Review

This is as critical as the ECG. Dozens of commonly used medications independently prolong the QT interval, and their combination with ibogaine creates an additive or synergistic risk that can be rapidly fatal.

QT-prolonging drugs that are absolute contraindications with ibogaine:

  • Methadone: One of the most clinically significant interactions. Methadone itself prolongs QT substantially, and combining it with ibogaine has caused multiple documented deaths. Patients must be transitioned off methadone — typically to short-acting opioids — well before ibogaine treatment. This process typically requires 2–4 weeks minimum and medical supervision.
  • Antipsychotics: Haloperidol, quetiapine, ziprasidone, chlorpromazine, clozapine.
  • Certain antidepressants: Tricyclic antidepressants (amitriptyline, clomipramine, imipramine), citalopram and escitalopram at higher doses.
  • Antiarrhythmics: Amiodarone, sotalol, quinidine, procainamide, flecainide — extreme contraindications.
  • Antibiotics: Azithromycin, clarithromycin, fluoroquinolones (ciprofloxacin, levofloxacin), fluconazole.
  • Antiemetics: Ondansetron (a commonly used anti-nausea medication given during ibogaine treatment must be avoided for this reason — alternatives like promethazine have their own interactions and require careful evaluation).
  • Stimulants: Cocaine and methamphetamine cause direct cardiac toxicity and are contraindications. Cocaine-associated QT prolongation combined with ibogaine has been implicated in deaths.

A full current medication list — including over-the-counter medications, herbal supplements, and substances of misuse — must be reviewed against the CredibleMeds QTDrugs database, which is the standard clinical reference for QT-drug interactions.

CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) also require a washout period because they slow ibogaine metabolism, potentially causing dangerously elevated ibogaine plasma levels.

4. Structural Cardiac Evaluation (Echocardiogram)

An echocardiogram is required or strongly recommended for:

  • Any patient over 45 years old
  • Patients with known or suspected heart disease
  • Patients with abnormal ECG findings
  • Patients with a history of heavy stimulant use (cocaine, methamphetamine), which causes structural cardiomyopathy
  • Patients with long-standing alcohol use disorder (alcoholic cardiomyopathy)
  • Patients with hypertension, diabetes, or hyperlipidemia
  • Patients with a family history of sudden cardiac death or inherited channelopathies

The echocardiogram evaluates left ventricular ejection fraction (LVEF), wall motion abnormalities, valvular disease, and structural abnormalities that substantially elevate ibogaine risk.

5. Cardiology Consultation

Any of the following findings require formal cardiology consultation — not just a primary care review — before ibogaine treatment can be considered:

  • QTc >440 ms (men) or >460 ms (women) on baseline ECG
  • Any arrhythmia beyond occasional isolated PACs
  • Prior myocardial infarction or coronary artery disease
  • LVEF below 50% on echocardiogram
  • Hypertrophic cardiomyopathy
  • History of syncope or unexplained loss of consciousness
  • Personal or family history of Long QT Syndrome (LQTS), Brugada syndrome, or catecholaminergic polymorphic ventricular tachycardia (CPVT)
  • Current use of any QT-prolonging medication that cannot be safely discontinued

Absolute Cardiac Contraindications to Ibogaine

The following conditions are hard contraindications. No responsible provider should administer ibogaine to a patient with these findings, regardless of other factors:

  • QTc >500 ms (most protocols; many use >450–470 ms)
  • Diagnosed Long QT Syndrome (congenital or acquired)
  • Brugada syndrome
  • Hypertrophic obstructive cardiomyopathy (HOCM)
  • Second- or third-degree atrioventricular (AV) block
  • Ventricular tachycardia or fibrillation (active or without implantable cardioverter-defibrillator)
  • Recent myocardial infarction (within 6 months; many protocols extend this to 12 months)
  • Severe valvular disease
  • Uncontrolled heart failure (LVEF <35%)
  • Active concurrent use of methadone or other high-risk QT-prolonging drugs that cannot be cleared
  • Severe uncorrected hypokalemia or hypomagnesemia that cannot be corrected prior to treatment
  • WPW syndrome

Intraoperative Cardiac Monitoring Requirements

Even with a clean cardiac workup, responsible ibogaine administration requires continuous cardiac monitoring throughout the experience. This includes:

  • Continuous pulse oximetry and vital sign monitoring for the full duration of the acute experience (typically 24–36 hours)
  • Cardiac telemetry or repeated 12-lead ECGs at baseline, 1 hour post-dose, peak effects (~4–6 hours), and during recovery
  • Immediate access to a defibrillator (AED or manual defibrillator) on-site
  • IV access established before administration
  • Magnesium sulfate IV available for emergent QT management
  • Medical personnel present with ACLS (Advanced Cardiac Life Support) training

The Global Ibogaine Therapist Alliance (GITA) clinical guidelines and the protocols used by academic institutions studying ibogaine (including the work of researchers at NYU and Stanford) all specify continuous monitoring as non-negotiable (Brown & Alper, 2018; Noller et al., 2018).

The Pre-Treatment Timeline

Cardiac preparation is not a same-day checklist. The following timeline reflects conservative best-practice protocols:

  • 4–8 weeks before treatment: Begin tapering or transitioning off QT-prolonging medications under medical supervision. Methadone transitions require at least 2–4 weeks and sometimes longer depending on dose.
  • 2–4 weeks before treatment: Complete cardiac workup (ECG, labs, echocardiogram if indicated). Address electrolyte deficiencies.
  • 1–2 weeks before treatment: Repeat ECG if initial findings were borderline or if medications have changed. Confirm electrolytes are within target range.
  • 24–48 hours before treatment: Confirm abstinence from all contraindicated substances. Final electrolyte optimization. Begin magnesium supplementation if not already initiated.
  • Day of treatment: Final vitals, rhythm check, IV access, emergency equipment confirmed.

What Happens If Screening Is Skipped

The consequences of bypassing cardiac screening are documented and severe. Published case series and regulatory reports include:

  • A 2014 review by Meisner et al. and subsequent analyses consistently show that the majority of ibogaine-associated fatalities involved patients who had one or more identifiable cardiac risk factors that were not screened for — including undiagnosed prolonged QTc, concurrent methadone use, or severe electrolyte abnormalities.
  • Deaths have occurred in otherwise apparently healthy individuals whose risk factors were discoverable only through ECG (e.g., subclinical LQTS) — reinforcing that clinical appearance alone is not sufficient.
  • Cardiac events during ibogaine treatment can occur during the peak psychedelic phase (when the patient may be unable to communicate symptoms) or during the recovery period (12–72 hours post-dose), when monitoring is often reduced in unregulated settings.
  • Underground and unregulated ibogaine providers who skip cardiac screening are directly implicated in the majority of ibogaine fatalities in the published literature.

Choosing a Provider: Cardiac Safety Questions to Ask

Before committing to any ibogaine provider, ask the following specific questions and verify the answers:

  • Do you require a 12-lead ECG within 14 days of treatment, read by a physician or cardiologist?
  • What is your QTc cutoff for disqualification from treatment?
  • Do you check serum potassium and magnesium and correct deficiencies before treatment?
  • Do you require patients on methadone to transition to a short-acting opioid before treatment?
  • Is continuous cardiac monitoring (telemetry or pulse oximetry) maintained for the full acute experience?
  • Is a defibrillator on-site and is someone ACLS-certified present throughout treatment?
  • What is your protocol if QTc exceeds threshold during treatment?

A provider who cannot answer these questions specifically, or who minimizes their importance, should not be trusted with ibogaine administration.

Frequently Asked Questions

Yes, unconditionally. Congenital Long QT Syndrome and other inherited channelopathies such as Brugada syndrome frequently produce no symptoms and no prior cardiac history — they are discovered on ECG or, tragically, at autopsy following sudden cardiac death. Several documented ibogaine fatalities have involved young adults in their 20s and 30s with no known cardiac history. A 12-lead ECG takes minutes and is low cost; there is no medical justification for skipping it regardless of age or apparent health.
Not while actively taking methadone. Methadone is one of the most potent QT-prolonging drugs in common use, and the combination with ibogaine has caused multiple confirmed deaths. A supervised medical transition from methadone to a short-acting opioid (such as morphine or oxycodone) — followed by a washout period — is required before ibogaine is safe to consider. This transition typically takes a minimum of 2–4 weeks and must be managed by a physician, not self-directed. The duration depends on your methadone dose; higher doses require longer transitions. This is a hard requirement, not a preference.
The QT interval on an ECG measures the time it takes your heart's ventricles to electrically reset between beats. The "c" in QTc means it's corrected for heart rate. When QTc is prolonged — generally above 450–470 ms depending on sex — the heart is vulnerable to a dangerous arrhythmia called torsades de pointes, where the ventricles begin firing chaotically. This can degrade into ventricular fibrillation (cardiac arrest) within seconds. Ibogaine prolongs QTc in virtually all patients, sometimes by 60–100 ms. If your baseline QTc is already elevated and ibogaine pushes it further, you enter a zone of very high arrhythmia risk. The QTc measurement itself is straightforward — what matters is having a qualified clinician interpret it in context.
Most responsible clinical protocols require the ECG within 14 days of treatment, and many specify 7 days. Bloodwork (electrolytes, metabolic panel, LFTs) is typically required within 30 days, with electrolytes repeated closer to treatment date if there is any concern about nutritional status or substance use. The reason for the short window is that cardiac status can change — electrolytes shift with drug use, hydration, and diet; new medication interactions can develop; and arrhythmias can appear. An ECG from 3 months ago does not clear you for ibogaine today. Verify your provider's specific timing requirements and ensure you get new labs if there is any gap or change in your health status.
Yes. This is a critically underappreciated risk. Noribogaine, ibogaine's primary active metabolite, has a half-life of 24–72 hours and is also a potent hERG channel blocker. QTc prolongation has been documented to persist for 24 hours or more after the acute psychedelic experience ends. This means patients are still at cardiac risk during the recovery period — when they may be unmonitored, sleeping, or discharged from supervision. Post-treatment cardiac monitoring for at least 24 hours, and ideally 48 hours, is part of best-practice protocols. Patients should not be left alone during this period, and any symptoms of palpitations, dizziness, or chest discomfort require immediate emergency evaluation.
No. This is a serious red flag and a valid reason to walk away from that provider. Survivorship bias — the fact that prior patients didn't die — does not make a practice safe. Many cardiac risk factors (subclinical Long QT Syndrome, borderline QTc, low magnesium) produce no outward symptoms. You cannot identify them without an ECG and bloodwork. Every major published clinical protocol for ibogaine, every academic research program studying ibogaine, and every regulatory framework where ibogaine is legally administered requires a pre-treatment ECG. A provider skipping this step is operating below the minimum standard of care, regardless of their experience level or track record.

Informational only. Not medical advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.